Foghorn Therapeutics Inc (FHTX)

$5.05

-0.25

(-4.72%)

Market is closed - opens 7 PM, 23 Apr 2024

Performance

  • $5.02
    $5.40
    $5.05
    downward going graph

    0.59%

    Downside

    Day's Volatility :7.04%

    Upside

    6.48%

    downward going graph
  • $2.70
    $9.97
    $5.05
    downward going graph

    46.53%

    Downside

    52 Weeks Volatility :72.92%

    Upside

    49.35%

    downward going graph

Returns

PeriodFoghorn Therapeutics Inc
3 Months
63.08%
6 Months
71.52%
1 Year
-14.38%
3 Years
-55.42%

Highlights

Market Capitalization
225.6M
Book Value
- $1.83
Earnings Per Share (EPS)
-2.34
Wall Street Target Price
13.75
Profit Margin
-288.17%
Operating Margin TTM
-441.29%
Return On Assets TTM
-19.53%
Return On Equity TTM
-470.38%
Revenue TTM
34.2M
Revenue Per Share TTM
0.81
Quarterly Revenue Growth YOY
37.9%
Gross Profit TTM
-86.4M
EBITDA
-104.5M
Diluted Eps TTM
-2.34
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.13
EPS Estimate Next Year
-1.34
EPS Estimate Current Quarter
-0.76
EPS Estimate Next Quarter
-0.69

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Foghorn Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
10
11
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 172.28%

Current $5.05
Target $13.75

Technicals Summary

Sell

Neutral

Buy

Foghorn Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Foghorn Therapeutics Inc
Foghorn Therapeutics Inc
-10.77%
71.52%
-14.38%
-55.42%
-70.75%
Moderna, Inc.
Moderna, Inc.
-3.81%
28.95%
-26.59%
-39.67%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.28%
12.73%
12.52%
82.86%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-4.7%
26.35%
43.96%
230.98%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.87%
7.24%
20.15%
82.55%
128.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Foghorn Therapeutics Inc
Foghorn Therapeutics Inc
NA
NA
NA
-2.13
-4.7
-0.2
NA
-1.83
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Foghorn Therapeutics Inc
Foghorn Therapeutics Inc
Buy
$225.6M
-70.75%
NA
-288.17%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
128.04%
28.33
36.68%

Institutional Holdings

  • Flagship Ventures Management, Inc.

    29.78%
  • FMR Inc

    6.60%
  • Raymond James & Associates

    4.86%
  • Euclidean Capital LLC

    3.70%
  • BlackRock Inc

    3.07%
  • Vanguard Group Inc

    2.41%

Corporate Announcements

  • Foghorn Therapeutics Inc Earnings

    Foghorn Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

foghorn therapeutics inc., a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. the company uses its proprietary gene traffic control platform to identify, validate, and potentially drug targets within the system. it is developing fhd-286, a small-molecule enzymatic inhibitor of brg1 and brm for the treatment of acute myeloid leukemia and uveal melanoma; and fhd-609, a small molecule protein degrader of brd9 to treat patients with synovial sarcoma. the company is also developing preclinical and discovery programs, including selective brm targeting non-small-cell lung cancer; and selective arid1b modulators for bladder, ovarian, and endometrial cancer. it has a collaboration with merck sharp & dohme corp. to discover and develop novel oncology therapeutics against a transcription factor target. the company was founded in 2015 and is headquartered in cambridge, massachusetts.

Organization
Foghorn Therapeutics Inc
Employees
116
CEO
Mr. Adrian H. B. Gottschalk
Industry
Health Technology

FAQs